Tectonic Therapeutic (NASDAQ:TECX) recently announced positive interim results from its phase 1b study using Fc-fusion protein TX45 for the treatment of patients with Group 2 pulmonary ...
26d
Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...
Tectonic Therapeutic TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ...
The TX45 treatment demonstrated significant improvements in left ventricular function and pulmonary hemodynamics, supporting the ongoing APEX Phase 2 clinical trial.
Tectonic Therapeutic, Inc.'s stock surged 120% after positive Phase 1b data for TX45 in treating PH-HFpEF, a condition with no approved therapies. TX45, an Fc-relaxin fusion protein, showed ...
The market's reaction reflects concerns over the future of TECX's lead product candidate, TX45, which targets the same RXFP1 receptor as Lilly's volenrelaxin. The termination of Lilly's ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...
The market's reaction reflects concerns over the future of TECX's lead product candidate, TX45, which targets the same RXFP1 receptor as Lilly's volenrelaxin. The termination of Lilly's volenrelaxin ...
Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback